Rocha K, Nascimento E, de Jesus R, Martins J
Molecules. 2024; 29(17).
PMID: 39275102
PMC: 11397288.
DOI: 10.3390/molecules29174254.
Khader A, Bokhari R, Hakimelahi R, Scheirey C, Afnan J, Braschi-Amirfarzan M
Eur J Radiol Open. 2022; 9:100406.
PMID: 35265736
PMC: 8899228.
DOI: 10.1016/j.ejro.2022.100406.
Yan Z, Shanmugasundaram K, Ma D, Luo J, Luo S, Rao H
J Biol Chem. 2020; 295(27):9069-9075.
PMID: 32439806
PMC: 7335801.
DOI: 10.1074/jbc.RA120.012821.
Li S, Lisanti M, Puszkin S
Bioquim Patol Clin. 2019; 62(1):5-17.
PMID: 31402847
PMC: 6688760.
Peiris M, Li F, Donoghue D
Oncotarget. 2019; 10(28):2738-2754.
PMID: 31105873
PMC: 6505627.
DOI: 10.18632/oncotarget.26837.
Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Huang N, Huang Z, Gao M, Luo Z, Zhou F, Liu L
J Exp Clin Cancer Res. 2018; 37(1):62.
PMID: 29554925
PMC: 5859405.
DOI: 10.1186/s13046-018-0732-4.
Inhibition of Ras-mediated signaling pathways in CML stem cells.
Bertacchini J, Ketabchi N, Mediani L, Capitani S, Marmiroli S, Saki N
Cell Oncol (Dordr). 2015; 38(6):407-18.
PMID: 26458816
DOI: 10.1007/s13402-015-0248-2.
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bernt K, Hunger S
Front Oncol. 2014; 4:54.
PMID: 24724051
PMC: 3971203.
DOI: 10.3389/fonc.2014.00054.
Translational genomics in cancer research: converting profiles into personalized cancer medicine.
Patel L, Parker B, Yang D, Zhang W
Cancer Biol Med. 2013; 10(4):214-20.
PMID: 24349831
PMC: 3860348.
DOI: 10.7497/j.issn.2095-3941.2013.04.005.
Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
Chen R, Hu T, Mahon G, Tala I, Pannucci N, Ozer H
Blood. 2013; 122(12):2114-24.
PMID: 23950177
PMC: 3778552.
DOI: 10.1182/blood-2013-01-481184.
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
Tala I, Chen R, Hu T, Fitzpatrick E, Williams D, Whitehead I
Leukemia. 2012; 27(5):1080-9.
PMID: 23207522
PMC: 3931524.
DOI: 10.1038/leu.2012.351.
LAT-independent Erk activation via Bam32-PLC-γ1-Pak1 complexes: GTPase-independent Pak1 activation.
Rouquette-Jazdanian A, Sommers C, Kortum R, Morrison D, Samelson L
Mol Cell. 2012; 48(2):298-312.
PMID: 22981863
PMC: 3483363.
DOI: 10.1016/j.molcel.2012.08.011.
Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients.
Koh Y, Kim D, Park S, Byun H, Kim I, Yoon S
Oncol Lett. 2012; 2(1):181-187.
PMID: 22870150
PMC: 3412470.
DOI: 10.3892/ol.2010.208.
Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.
Yu W, Sun X, Tang H, Tao Y, Dai Z
Leuk Lymphoma. 2010; 51(6):1098-107.
PMID: 20536348
PMC: 2885034.
DOI: 10.3109/10428191003754624.
SH2-dependent autophosphorylation within the Tec family kinase Itk.
Joseph R, Severin A, Min L, Fulton D, Andreotti A
J Mol Biol. 2009; 391(1):164-77.
PMID: 19523959
PMC: 2722949.
DOI: 10.1016/j.jmb.2009.06.023.
Proline isomerization preorganizes the Itk SH2 domain for binding to the Itk SH3 domain.
Severin A, Joseph R, Boyken S, Fulton D, Andreotti A
J Mol Biol. 2009; 387(3):726-43.
PMID: 19361414
PMC: 2810249.
DOI: 10.1016/j.jmb.2009.02.012.
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
J Cell Mol Med. 2009; 13(2):215-37.
PMID: 19175693
PMC: 3823350.
DOI: 10.1111/j.1582-4934.2008.00559.x.
Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells.
Alexis J, Wang N, Che W, Lerner-Marmarosh N, Sahni A, Korshunov V
Circ Res. 2008; 104(1):69-78.
PMID: 19023129
PMC: 2642522.
DOI: 10.1161/CIRCRESAHA.108.188409.
Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components.
Yogalingam G, Pendergast A
J Biol Chem. 2008; 283(51):35941-53.
PMID: 18945674
PMC: 2602914.
DOI: 10.1074/jbc.M804543200.
Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects.
Perazzona B, Lin H, Sun T, Wang Y, Arlinghaus R
Oncogene. 2007; 27(15):2208-14.
PMID: 17934518
PMC: 2585769.
DOI: 10.1038/sj.onc.1210851.